Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)

SHE:300357 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Cash & Equivalents	775.51	797.22	1,119	1,171	840.69	649.99
Short-Term Investments	200.05	74.58	-	-	-	-
Trading Asset Securities	558.75	560.23	196.09	117.39	295.05	370.93
Cash & Short-Term Investments	1,534	1,432	1,315	1,289	1,136	1,021
Cash Growth	14.34%	8.91%	2.03%	13.47%	11.25%	14.62%
Accounts Receivable	377.83	242.93	251.04	202.92	254.31	238.12
Other Receivables	6.2	6.09	6.83	-	19.81	11.13
Receivables	384.04	249.03	257.87	202.92	274.12	249.26
Inventory	47.98	54.76	57.73	59.04	48.41	53.75
Other Current Assets	9.72	25.43	20.95	19.17	18.86	17.58
Total Current Assets	1,976	1,761	1,651	1,570	1,477	1,342
Property, Plant & Equipment	776.36	842.85	780.09	704.84	444.61	301.62
Long-Term Investments	296.47	108.32	77.94	74.21	78.4	83.35
Other Intangible Assets	119.5	149.46	162.79	161.38	139.67	94
Long-Term Deferred Tax Assets	6.77	5.58	5.6	5.03	4.87	5.81
Long-Term Deferred Charges	34.53	26.31	25.27	34.38	53.2	86.05
Other Long-Term Assets	7.4	3.64	5.94	12.42	-	19.63
Total Assets	3,217	2,897	2,709	2,562	2,198	1,932

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Accounts Payable	61.12	31.41	47.77	7.99	7.68	5.08
Accrued Expenses	26.32	37.27	35.13	33.57	29.89	35.54
Short-Term Debt	-	5	12.63	34.39	-	-
Current Portion of Leases	4.43	4.08	5.03	6.8	3.98	5.86
Current Income Taxes Payable	61.34	1.98	10.56	9.26	26.08	50.32
Current Unearned Revenue	0.58	0.53	0.51	0.38	0.42	0.42
Other Current Liabilities	9.37	64.3	70.95	84.64	34.71	10.78
Total Current Liabilities	163.16	144.57	182.58	177.04	102.75	108
Long-Term Leases	7.71	9.32	7.93	21.26	12.28	1.95
Long-Term Unearned Revenue	30.24	31.74	33.53	30.93	27.43	24.91
Long-Term Deferred Tax Liabilities	0.06	0.03	0.17	0.2	0.08	0.5
Other Long-Term Liabilities	-	-	26.08	29.03	28.22	-
Total Liabilities	201.18	185.67	250.3	258.46	170.76	135.36

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Common Stock	523.58	523.58	523.58	523.58	523.58	523.58
Additional Paid-In Capital	128.19	128.19	128.19	128.19	128.19	128.19
Retained Earnings	2,280	1,968	1,702	1,533	1,328	1,084
Comprehensive Income & Other	0.02	0.03	0.04	0.03	0.03	0
Total Common Equity	2,932	2,619	2,354	2,185	1,980	1,736
Minority Interest	83.7	92.27	105.12	118.61	47.49	60.54
Shareholders' Equity	3,016	2,712	2,459	2,304	2,027	1,797
Total Liabilities & Equity	3,217	2,897	2,709	2,562	2,198	1,932

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Total Debt	12.15	18.41	25.59	62.44	16.26	7.81
Net Cash (Debt)	1,522	1,414	1,289	1,226	1,119	1,013
Net Cash Growth	15.09%	9.64%	5.14%	9.54%	10.50%	13.74%
Net Cash Per Share	2.91	2.70	2.46	2.34	2.14	1.93
Filing Date Shares Outstanding	523.58	523.58	523.58	523.58	523.58	523.58
Total Common Shares Outstanding	523.58	523.58	523.58	523.58	523.58	523.58
Working Capital	1,813	1,617	1,469	1,393	1,374	1,234
Book Value Per Share	5.60	5.00	4.50	4.17	3.78	3.32
Tangible Book Value	2,813	2,470	2,191	2,024	1,840	1,642
Tangible Book Value Per Share	5.37	4.72	4.18	3.87	3.51	3.14
Buildings	-	638.01	428.52	423.31	175.67	137.89
Machinery	-	168.95	135.42	115.99	95.51	77.11
Construction In Progress	-	175.46	323.16	227.86	226.24	140.33

Data Source: S&P Global Market Intelligence Last updated: Oct 23, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 28, 2026

Data Sources Report a data error